ประสิทธิผลของยาออกซีเมทโทโลนเมื่อใช้ร่วมกับยาอิริโธรพอยอิติน ในผู้ป่วยล้างไตทางช่องท้องแบบถาวร / สุทธิวรรณ วิวัฒนิวงศ์ = The efficacy of oxymetholone in combination with recombinant human erythropoietin in continuous ambulatory peritoneal dialysis patients / Suttiwan Wiwatniwong
Objectives: To determine the efficacy of oxymetholone when using combination with recombinant human erythropoietin (rHuEPO) in continuous ambulatory peritoneal dialysis (CAPD) patients. Methods: A double blinded, placebo-controlled experimental study was conducted during October, 2003 to March, 2005 at CAPD clinic, Phramongkutklao Hospital. Eight-teen CAPD patients were divided into two groups. Group A (n=9) received rHuEPO plus oral oxymetholone 50 mg/tablet twice daily for six months. Group B (n=9) received rHuEPO plus placebo twice daily for six months. The evolution of hematologic parameters and the impact on nutritional parameters such as anthropometric parameters, biochemical variables, lean body mass (LBM) measured by dual energy x-ray absorptiometry (DEXA) and subjective global assessment (SGA) score were evaluated after six months of treatment. Results: After six month therapy, hematocrit and hemoglobin values of the group receiving rHuEPO plus oxymetholone was significantly different from the rHuEPO plus placebo-group (38.7+-2.3% and 33.0+-3.9%, p=0.002 for hematocrit; 13.1+-0.9 g/dL and 11.1+-1.3 g/dL, p=0.002 for hemoglobin, respectively). The increase in hematocrit and hemoglobin in the oxymetholone group was statistically greater than the placebo group (p<0.01). At the end of the study, no anthropometric parameters, albumin, protein and LBM were significantly different compare to baseline in the placebo group. Conversely, anthropometric parameters (weight, body mass index, biceps skinfold, triceps skinfold and mid-arm circumference), albumin and total protein significantly increased in the oxymetholone group (p<0.05). LBM of oxymetholone group changed from 735.22+-45.84 to 781.72+-73.38 g/kg (p=0.014). The SGA score was changed to better trend in 6 patients (66.7%). No difference in protein and energy intake in both groups. A reversible rise in the liver enzymes and high density lipoprotein were the main side effect observed in oxymetholone group. Conclusions: Oxymetholone significantly enhances the erythropoietic effects of rHuEPO and improves nutritional status in CAPD patients, but still significant increases liver enzyme.